Legend Capital
Legend hits first close on healthcare fund, launches TMT vehicle
Legend Capital has reached a first close of $177 million on its third US dollar-denominated China healthcare fund. It is one of five vehicles the GP has in the market, including its recently launched ninth flagship technology, media, and telecom (TMT)...
China e-commerce SaaS player Huice raises $312m
Huice, a China-based provider of software for e-commerce retailers, has raised $312 million in a Series D round led by SoftBank Vision Fund 2. This is the largest single round in China’s software-as-a-service (SaaS) industry year-to-date.
China data storage software start-ups gets $110m
Boyu Capital has led a RMB710 million ($110 million) Series E round for China-based data storage software services provider XSKY.
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.
China education: Opportunity erased?
Private equity investors have pumped billions of dollars into Chinese online education platforms, notably in the K-12 space. A regulatory crackdown has left them wondering how they can get their money back
China cancer screening specialist raises $99m
China Merchants Capital has led a $99.5 million funding round for Berry Oncology Corporation, an early cancer screening spin-out from China-based genetic testing specialist Berry Genomics.
China AI drug developer BioMap raises $100m
GGV Capital has led a $100 million Series A round for BioMap, a China-based biological computing platform. It marks the first time the company has sought external funding.
China community group buying platform Tongcheng Life goes bust
Tongcheng Life, a China-based community group buying business incubated by online travel agency Tongcheng-Elong, has announced its bankruptcy, blaming "poor management."
China trucking player secures $200m Series E
For-U Smart Freight, a Chinese road freight logistics company, has raised a $200 million Series E round led by China Structural Reform Fund, China life Investment, and Greater Bay Area Homeland Investments.
Legend closes China healthcare continuation fund
Legend Capital has spun out the healthcare assets from two of its China venture capital funds into a continuation vehicle supported by Hamilton Lane and Coller Capital. The $270 million deal includes capital for follow-on investments.
China medical tech supplier AMS raises $100m
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
Chinese contact lens brand raises $65m
Dearer Medical, a Shanghai-based cosmetic contact lens manufacturer, has raised RMB420 million ($65 million) in Series B funding from CPE, Legend Capital, and Insight Capital.
China home fitness brand Fiture raises $300m
Fiture, a Chinese developer of artificial intelligence-enabled home fitness devices, has raised $300 million in Series B funding led by All-Stars Investment, Legend Capital, DST Global, and Coatue Management.
China's Baidu raises funding for chip unit at $2b valuation
CPE has led a funding round for Kunlun, the semiconductor unit of Chinese search giant Baidu, at a post-deal valuation of approximately RMB13 billion ($2 billion).
China cancer screening business gains on Hong Kong debut
New Horizon Health, a China-based and venture capital-backed cancer early screening company, rose 215% on its trading debut following a HK$2 billion ($258 million) Hong Kong IPO.
Eastern Bell, Hidden Hill join $512m China air cargo deal
Eastern Bell Capital and Hidden Hill Capital, the private equity arm of warehousing and logistics player GLP, have participated in a RMB3.35 billion ($512 million) funding round for the freight business of China Southern Airlines.
PE-backed Harbour BioMed raises $221m in Hong Kong IPO
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
China retail SaaS provider Huice secures $100m Series C
Huice, a China-based provider of software for retailers, has raised nearly $100 million in Series C funding led by Singapore’s GIC. GL Ventures, Legend Capital and SoftBank Ventures Asia also participated in the round.
Legend closes eighth China VC fund on $500m
Legend Capital has closed its eighth US dollar-denominated venture capital fund at the hard cap of $500 million, continuing the rich vein of China VC fundraising.
China rebound favors the few - AVCJ Forum
China’s economy has rebounded from COVID-19 faster than most others, but the pandemic has exposed a widening wealth gap in the country, industry participants told the AVCJ China Forum.
Legend leads $20m Series B for China's Exegenesis Bio
Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Deal focus: Haihe's biotech out-licensing ambition
Warburg Pincus picked Haihe Pharmaceutical as its first bet on innovative drug development in China, having been convinced by the company's mature portfolio and international expansion plans
Investigation confirms fraud at China's Luckin Coffee
Private equity-backed Chinese coffee shop chain Luckin Coffee has confirmed earlier suspicions of large-scale financial fraud in its operations, while a proposal to remove the company’s chairman failed to receive enough shareholder support.